1.05
전일 마감가:
$0.9502
열려 있는:
$0.9502
하루 거래량:
426.74K
Relative Volume:
0.08
시가총액:
$11.29M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.0686
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
+23.67%
1개월 성능:
-3.67%
6개월 성능:
-58.82%
1년 성능:
-75.58%
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
MBRX
Moleculin Biotech Inc
|
1.05 | 11.29M | 0 | -29.77M | -24.23M | -15.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech Releases Corporate Presentation Online - TipRanks
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) - Aktiellt
Moleculin Biotech’s Annamycin Highlighted at AACR 2025 - TipRanks
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 | MBRX Stock News - GuruFocus
Moleculin Announces Acceptance of Abstract to be Presented - GlobeNewswire
Major Cancer Research Breakthrough: Moleculin's Annamycin Drug Combinations Study Heads to AACR 2025 - Stock Titan
Moleculin Biotech adjourns special meeting due to lack of quorum By Investing.com - Investing.com South Africa
Moleculin Biotech adjourns special meeting due to lack of quorum - Investing.com Australia
Moleculin Reports Second Quarter 2023 Financial Results - Seeking Alpha
Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance
Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks
Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener
Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan
Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN
What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World
Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN
Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World
Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN
Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World
Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq
H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com
Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright - Defense World
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: P - GuruFocus
Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks
Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials By Investing.com - Investing.com South Africa
Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials - Investing.com
Moleculin Biotech Inc Reports Q4 Earnings: EPS of -$1.28, Revenue at $0 Million, Aligns with Analyst Estimates - GuruFocus
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Moleculin Biotech Shares Corporate Presentation Update - TipRanks
FDA-Optimized Phase 3 AML Trial: Moleculin Cuts Costs, Expands to Europe - Stock Titan
Moleculin Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Moleculin Biotech, Inc. SEC 10-K Report - TradingView
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire
Moleculin Biotech Prepares to Unveil Critical 2024 Financial Performance - Stock Titan
Moleculin Biotech Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView
Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference - PR Newswire
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):